Established within the Vision Institute since 2008, Horus Pharma benefits from an advanced research environment, internationally recognised for its work in the field of ophthalmology.
Built in the heart of the Quinze-Vingts National Eye Hospital and managed by Prof. José Alain Sahel, the Vision Institute is the first integrated research centre in Europe, dedicated entirely to eye diseases.
Supported by INSERM and Pierre and Marie Curie University, this multidisciplinary research institute aims to share knowledge and techniques to quickly reach new milestones in the areas of eye disease and vision. In 6000 m² of space, researchers, clinicians and industry partners collaborate to understand, discover and test the treatments and technological innovations of tomorrow.
Horus Pharma creates Art Ophta, an unprecedented charitable operation combining artistic creation in ophthalmology.
True to their values, Horus Pharma laboratories wish to promote innovation and make it accessible. This is also true for artistic creation.
The idea is first to share the artist’s through process on «Contemporary Art & Ophthalmology», through the implementation of new works, exploring the enigma of vision. Produced in limited editions, these creations are then presented and discussed among ophthalmologists. This is an opportunity to discuss new aspects of their speciality.
Art Ophta operation stood out for some great collaborations with artists Sacha Sosno and Michel Bisbard, around the themes of visual obliteration and modular Art.
The next step is to promote these works to practitioners for the benefit humanitarian actions. All funds raised through the generosity of the doctors are donated to the charity SHARE association which works to promote world health.
Supported by Eurobiomed, Horus Pharma co-founded and is chair of Ophta Biotech, an association that brings together actors in ophthalmology in the Mediterranean arc.
Co-founded in 2009 by Claude Claret (Horus Pharma), Pierre-Paul Elena (Iris Pharma), Prof. Pierre Gastaud (Nice University Hospital) and Dr. Loïc Lozivit (ophthalmologist, Nice), Ophta Biotech brings together actors in diagnostics, therapy and research in ophthalmology for patient associations in the Mediterranean arc.
Based on the pooling of multidisciplinary expertise and dialogue with patients, Ophta Biotech promotes the emergence of projects and new tools for visually impaired people. The main tasks of the association are to:
Ophta Biotech is a member of Eurobiomed, competitiveness cluster in the Health industry that actively supports the dynamic of research initiated by the association.